Skin and Connective Tissue-Derived Proteins and Peptides: CIR Safety Assessment Summary
CIR safety assessment summary for Skin and Connective Tissue-Derived Proteins and Peptides: ingredients reviewed, panel verdict, use concentration context.
Skin and Connective Tissue-Derived Proteins and Peptides appears in a CIR safety assessment covering Skin and Connective Tissue-Derived Proteins and Peptides. The panel verdict for the report is safe. The Expert Panel for Cosmetic Ingredient Safety concluded that the 19 skin and connective tissue-derived proteins and peptides listed below are safe in cosmetics in the present practices of use and concentration described in this safety assessment.
| Field | CIR value |
|---|---|
| Primary ingredient | Skin and Connective Tissue-Derived Proteins and Peptides |
| CIR verdict | safe |
| Report type | Safety Assessment |
| Date | Toxicology 2022 |
| CAS numbers | 68951-88-2, 73049-73-7, 92113-31-0, 9007-34-5, 55963-88-7, 9000-70-8, 68410-45-7, 99924-37-5, 9007-58-3, 049-73-7, 91080-18-1, 98725-78-1 |
| Use concentration context | present practices of use and concentration described in the safety assessment |
| Conditions or carve-outs | Not reported to be in current use |
Ingredients Reviewed
The review scope matters because CIR conclusions often apply to an ingredient family rather than a single INCI name. In this report, the ingredient list includes Skin and Connective Tissue-Derived Proteins and Peptides.
Safety Conclusion
The conclusion for Skin and Connective Tissue-Derived Proteins and Peptides should be read as a CIR panel conclusion, not a regulatory limit. CIR assessments summarize expert-panel safety determinations for cosmetic use, while legal status still depends on the jurisdiction and product category.
For use levels, the report gives this concentration context: present practices of use and concentration described in the safety assessment. That language is the safe-use context shown for this page.
Conditions
Not reported to be in current use
Formulation Reading
For formula review, begin with the exact INCI identity and the ingredient group covered by the CIR assessment. If the material is Skin and Connective Tissue-Derived Proteins and Peptides, the relevant comparison is whether the intended use aligns with the practices, concentration ranges, and conditions described in the CIR source.
The ingredient hub at Skin and Connective Tissue-Derived Proteins and Peptides should carry the substance-level profile. This page is the report-level summary, keeping the conclusion, ingredient scope, and use-context language attached to the CIR source rather than treating the conclusion as a universal permission.
Why This Page Exists
CIR reviews are long documents, and the practical answer is usually buried in the conclusion and the table of current practices. This summary keeps those CIR facts in one indexable page for Skin and Connective Tissue-Derived Proteins and Peptides, with source details retained at the bottom for audit.
Review Notes
The conservative reading is to keep Skin and Connective Tissue-Derived Proteins and Peptides tied to the exact CIR report listed below. The ingredient family, panel conclusion, date, and any use-condition language belong together. A shorter ingredient-page snippet would lose that context.
This page gives the search-level answer while preserving the source-level caveat: CIR safety language is a panel assessment for cosmetic practices of use, not a universal legal permission across every jurisdiction or product category.
Source
- CIR report: Safety Assessment of Skin and Connective Tissue-Derived Proteins and Peptides as Used in Cosmetics Christina L. Burnett*, Wilma F. Bergfeld**, Donald V. Belsito**, Ronald A. Hill***, Curtis D. Klaassen**, Daniel C. Liebler**, James G. Marks
- CIR source file: PRS744.pdf
- Extraction JSON: CIR Safety Assessment Database
- Conclusion page in CIR extraction: 20